Rami Manochakian MD, FASCO Cancer Education (@RManochakian) / X

Rami Manochakian MD, FASCO Cancer Education

3,988 posts

Rami Manochakian MD, FASCO Cancer Education

@RManochakian

Associate Professor/Thoracic Oncologist/Vice Chair-Education/#HemOnc Fellowship Director @MayoClinic FL/Assoc Editor @ASCO #Education #LungCancer #أورام #طبيب

Jacksonville, FL

mayoclinic.org/biographies/ma…

Joined February 2021

Pinned
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Aug 29, 2021
“When Cancer Hits the Oncologist’s Home”. On the anniversary of his passing, I share a piece I published @OncJournal on my experience as a cancer doctor, during my father-in-law’s cancer journey. He’s a great man who beat cancer by fighting the cancer. RIP theoncologist.onlinelibrary.wiley.com/doi/full/10.16…
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Apr 24, 2023
I’m Humbled & Honored to receive the: 2023 #TeacherOfTheYear #Award by the @MayoClinic Fellows Association. “When ONE teaches, TWO learn.” R. Heinlein I’m blessed, proud & grateful to work with the BEST #Fellows & #Residents, to teach them & to learn from them. @MayoCancerCare
26K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Apr 1, 2025
🙏Sharing an #Honor I’m deeply #Humbled & Thankful to receive; The 2025 @MayoClinic #TeacherOfTheYear #Award. “When ONE teaches, TWO learn.” R. Heinlein I’m blessed, grateful & proud to work with THE BEST #Hematology/#Oncology #Fellows, to #Teach them, and to #Learn from them.
9.4K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Nov 8, 2023
I’m honored & humbled to earn the distinction of #FASCO (Fellow of the American Society of Clinical Oncology) @ASCO. It’s been such an honoring & fulfilling experience to serve & contribute to the great mission of a great society (@ASCO) and work with amazing staff & colleagues.
ASCO
@ASCO
Nov 8, 2023
🎉 Join us in congratulating the following members on earning the Fellow of ASCO (FASCO) distinction this quarter! We're grateful for your extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about the FASCO distinction: brnw.ch/21wEhng
20K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Jun 3, 2023
🚨🔥@OncoAlert Hot off the press. Just published @NEJM, in conjunction with presentation @ASCO #ASCO23 by the great Dr. @HwakeleeMD & team: Results of #Keynote671 Trial: “Perioperative #Pembrolizumab for Early-Stage Non–Small-Cell #LungCancer” 👇🏼 nejm.org/doi/full/10.10…
30K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Jun 4, 2023
🚨🔥@OncoAlert Hot off the press. Just published @NEJM, in conjunction with presentation @ASCO #ASCO23 plenary session by @DrRoyHerbstYale & team. #OverallSurvival Results of #ADAURA Trial: “Adjuvant #Osimertinib in resected #EGFR‑mutant #NSCLC” 👇🏼 nejm.org/doi/full/10.10…
28K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Jun 2, 2024
I’m honored & humbled to receive the distinction of #FASCO (Fellow of the American Society of Clinical Oncology) @ASCO #ASCO24 It’s been an honoring & fulfilling experience to serve & contribute to the GREAT mission of a GREAT society @ASCO along with GREAT staff & colleagues.
5.6K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Mar 17, 2025
🚨🔥@OncoAlert Hot off the press Just published @NatureMedicine Results of longitudinal analysis of #Molecular #Residual #Disease (#MRD) from #ADAURA phase 3 trial of adjuvant #Osimertinib in resected #EGFR+ stage IB–IIIA non-small-cell #LungCancer 👇🏻 nature.com/articles/s4159…
13K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
May 12, 2025
1/3🧵 🔥Hot off the press. ⭐️My co-authors & I are excited to share this just published paper @ASCO #ASCO25 #ASCOEdBook on a topic that is near & dear to my heart: ✅“The ART of #Oncology #Education & #Knowledge Sharing. It is All About the “#How” 👇🏻 ascopubs.org/doi/10.1200/ED…
27K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Dec 27, 2024
🔥🚨@OncoAlert Hot off the press. @US_FDA approved #Subcutaneous #Nivolumab for: ✅All adult indications in #SolidTumors ❌EXCEPT for combination with #Ipilimumab Approval based on #CHECKMATE67T which showed similar #Efficacy & #Safety of #SQ vs #IV 👇🏼 fda.gov/drugs/resource…
15K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Sep 10, 2023
🔥🚨Hot off the press, presented @IASLC #WCLC23, results of ETER701, phase 3 trial of Benmelstobar+Anlotinib+Chemo vs Placebo+Chemo in 1st line therapy for extensive stage ES #SCLC Unprecedented historical IMPROVEMENT in #PFS & #OS mPFS 6.9 vs 4.2 months mOS 19.3 vs 11.9 months
70K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Oct 23, 2023
🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO23. “Results of #AEGEAN trial of #Perioperative #Durvalumab (or #placebo) + neoadjuvant chemo in #Patients with respectable stage II-IIIB #NSCLC.” 👇🏼 nejm.org/doi/full/10.10…
29K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Jan 31, 2023
🔥🔥🚨🚨HOT OFF THE PRESS. Just published at @JCO_ASCO @ASCO by @DrRoyHerbstYale & colleagues. Updated Results of #ADAURA Trial: #Adjuvant #Osimertinib for Resected #EGFR mutant Stage IB-IIIA Non-Small Cell #LungCancer. 👇🏼Article & major results figures ascopubs.org/doi/pdf/10.120…
41K
Rami Manochakian MD, FASCO Cancer Education
@RManochakian
Jun 6, 2023
🔥🚨@OncoAlert #ASCO23 NEGATIVE results of #Keynote789 trial: Platinum + Pem +/- Pembro for TKI-resistant #EGFR mutant #NSCLC ❌PFS HR 0.8, P=0.0122 mPFS: 5.6 vs 5.5 mths ❌OS HR 0.84, P=0.0362 mOS: 15.9 vs 14.7 mths After TKI , adding Pembro to chemo DOES NOT improve OS
41K